Join
Live feed
·
NEWSReleasevia Quantisnow
vTv Therapeutics Inc. logo

vTv Therapeutics Screens First Patient In CATT1 Pivotal Trial Evaluating Cadisegliatin For Type 1 Diabetes

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VTVT (vTv Therapeutics Inc.) and more on Quantisnow.